Literature DB >> 32484764

Natural Product Inhibitors of Cyclooxygenase (COX) Enzyme: A Review on Current Status and Future Perspectives.

Goutami G Ambati1, Sanjay M Jachak1.   

Abstract

BACKGROUND: Several clinically used COX-1 and COX-2 inhibitor drugs were reported to possess severe side effects like GI ulcers and cardiovascular disturbances, respectively. Natural products being structurally diverse always attracted the attention of chemists/ medicinal chemists as a potential source of lead molecules in the drug discovery process. COX-2 inhibitory natural products also possess potential cancer chemopreventive property against various cancers including that of colon, breast and prostate.
METHODS: Various in vitro, in vivo and in silico standardized methods were used to evaluate COX inhibition property of different secondary metabolites isolated from plant, microbial and marine origin.
RESULTS: We had earlier reported a detailed account of natural product inhibitors of COX reported during 1995-2005, in 2006. In the proposed review, we report 158 natural product inhibitors of COX during 2006 to 2019 belonging to various secondary metabolite classes such as alkaloids, terpenoids, polyphenols as flavonoids, chromones, coumarins, lignans, anthraquinones, naphthalenes, curcuminoids, diarylheptanoids and miscellaneous compounds of plant and marine origin. Further Structure Activity Relationship (SAR) studies of possible leads are also included in the article.
CONCLUSION: COX inhibitors served as a potential source of lead molecules for the discovery and development of anti-inflammatory drugs. Compilation of natural product and semisynthetic inhibitors of COX may serve as valuable information to the researchers who are looking for possible lead molecules from a natural source to conduct further preclinical and clinical studies. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Cyclooxygenase-1 (COX-1); antiinflammatoryzzm321990activity; cancer; cyclooxygenase-2 (COX-2); natural product COX inhibitors; secondary metabolites

Mesh:

Substances:

Year:  2021        PMID: 32484764     DOI: 10.2174/0929867327666200602131100

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  5 in total

Review 1.  Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors.

Authors:  Mohsen Ahmadi; Sander Bekeschus; Klaus-Dieter Weltmann; Thomas von Woedtke; Kristian Wende
Journal:  RSC Med Chem       Date:  2022-02-14

2.  Oral administration of E-type prostanoid (EP) 1 receptor antagonist suppresses carcinogenesis and development of prostate cancer via upregulation of apoptosis in an animal model.

Authors:  Masahito Masato; Yasuyoshi Miyata; Hiroki Kurata; Hidenori Ito; Kensuke Mitsunari; Akihiro Asai; Yuichiro Nakamura; Kyohei Araki; Yuta Mukae; Tsuyoshi Matsuda; Junki Harada; Tomohiro Matsuo; Kojiro Ohba; Hideki Sakai
Journal:  Sci Rep       Date:  2021-10-13       Impact factor: 4.379

3.  Synthesis of Copper Oxide-Based Nanoformulations of Etoricoxib and Montelukast and Their Evaluation through Analgesic, Anti-Inflammatory, Anti-Pyretic, and Acute Toxicity Activities.

Authors:  Sulaiman Sulaiman; Shabir Ahmad; Syeda Sohaila Naz; Sara Qaisar; Sayyar Muhammad; Amal Alotaibi; Riaz Ullah
Journal:  Molecules       Date:  2022-02-21       Impact factor: 4.411

4.  A Copper-Based Biosensor for Dual-Mode Glucose Detection.

Authors:  Kai Li; Xiaoyu Xu; Wanshan Liu; Shouzhi Yang; Lin Huang; Shuai Tang; Ziyue Zhang; Yuning Wang; Fangmin Chen; Kun Qian
Journal:  Front Chem       Date:  2022-04-04       Impact factor: 5.545

5.  Natural Cyclooxygenase-2 Inhibitors Synergize With Butyrate to Augment Chicken Host Defense Peptide Gene Expression.

Authors:  Qing Yang; Amanda C Burkardt; Lakshimi T Sunkara; Kan Xiao; Guolong Zhang
Journal:  Front Immunol       Date:  2022-02-22       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.